RESUMEN
This study shows the feasibility of a beam emission spectroscopy (BES) diagnostic in the Helically Symmetric eXperiment (HSX) stellarator for obtaining the spatiotemporal structure of density fluctuation. A beam emission simulation was applied to HSX plasmas to design and optimize viewing chords and to estimate the beam emission spectrum. A Doppler-shifted beam emission spectrum was measured from a 30 kV, 4 A diagnostic neutral beam injected into HSX plasmas. The beam emission was measured with a high-time-resolution avalanche photodiode (APD) assembly to determine the feasibility of BES in HSX. For HSX plasmas heated by 28 GHz electron cyclotron heating, a mode around f = 15 kHz was observed in the BES signal. The coherence between the BES signal and the density fluctuation measured by an interferometer system was significant. A plan for improving the BES system to enable the measurement of higher frequency related to turbulent transport is presented. The array of sightlines proposed in this study can be used to measure beam emission with a Doppler shift larger than 3 nm (blue shift), which enables the use of a wide passband interference filter to obtain higher throughput. The adoption of a large objective optics and a chilled APD assembly will improve the signal-to-noise ratio.
RESUMEN
BACKGROUND: Healthcare-associated infections (HAIs) are a significant cause of increased medical costs, morbidity, mortality, and have been partly associated with sinks, their waste water outlets and associated pipework. AIM: To determine whether an engineered sink could limit microbial aerosol contaminants in the air and sink basin. METHODS: Multiple comparisons were undertaken between an experimental sink, designed to limit aerosolization and p-trap contamination to a control hospital sink, both connected to a common drain system. The experimental sink was equipped with ultraviolet light (UV), an aerosol containment hood, ozonated water generator and a flush system to limit bacterial growth/aerosolization and limit microbial growth in the p-trap. Nutrient material was added daily to simulate typical material discarded into a hospital sink. Surface collection swabs, settle plates and p-trap contamination levels were assessed for bacteria and fungi. FINDINGS: The experimental sink had significantly decreased levels of bacterial and fungal p-trap contamination (99.9% for Tryptic Soy (TSA) and Sabouraud agar (SAB) plates) relative to the initial levels. Aerosol-induced contaminant from the p-traps was significantly lower for the experimental vs the control sink for TSA (76%) and SAB (86%) agar settle plates. CONCLUSIONS: Limiting microbial contamination is critical for the control of nosocomial infections of in-room sinks, which provide a major source of contamination. Our experimental sink studies document that regular ozonated water rinsing of the sink surface, decontamination of p-trap water, and UV decontamination of surfaces limits microbial aerosolization and surface contamination, with potential to decrease patient exposure and reduce hospital acquired infections.
Asunto(s)
Aerosoles , Bacterias/aislamiento & purificación , Diseño de Equipo , Equipos y Suministros/microbiología , Hongos/aislamiento & purificación , Instituciones de Salud , Aguas Residuales , Bacterias/crecimiento & desarrollo , Desinfección/métodos , Hongos/crecimiento & desarrollo , Humanos , Purificación del Agua/métodosRESUMEN
Lenalidomide (LEN) and metronomic cyclophosphamide (CTX) regulate angiogenesis and immunosuppressive cells linked to the progression of metastatic castration-resistant prostate cancer (mCRPC). A phase-I/II, dose-escalation trial of LEN plus oral CTX was conducted in patients with previously treated mCRPC. In the phase-I study, CTX was given at 50 mg (day 1-28) and LEN at 10-25 mg (day 1-21) on a 28-day cycle using a "3+3" study design. In phase II, patients received LEN at 25 mg (day 1-21) with CTX at 50 mg PO QD (day 1-28) on a 28-day cycle. Nineteen patients in phase I were evaluable for toxicity. The maximum tolerated dose (MTD) was not observed at any of the dose levels (DLs) tested. Six patients received treatment in phase II before the trial was closed. A ≥ 50% reduction in PSA was observed in 31.7% evaluable patients. Radiographically, one patient had a partial response. Stable disease was documented in 68% of evaluable patients after two therapy cycles. Circulating tumor cells (CTCs) decreased in 22.7% and remained stable in 31.8% of patients. Baseline numbers of peripheral MDSCs (MDSC; Lin-DR(-)CD11b(+)) were significantly increased in patients versus normal donors, and were decreased by chemotherapy. At baseline, MDSCs correlated directly with CTCs, and inversely with T- and B cell frequency supporting their immunosuppressive activity. The combination of LEN and metronomic CTX can be safely administered, reversing cellular immunosuppression in this group of elderly patients with mCRPC. Further research is required to identify responsive subgroup(s) and validate the biomarkers.
Asunto(s)
Ciclofosfamida/uso terapéutico , Regulación Neoplásica de la Expresión Génica , Inmunosupresores , Neoplasias de la Próstata Resistentes a la Castración/tratamiento farmacológico , Talidomida/análogos & derivados , Anciano , Anciano de 80 o más Años , Antineoplásicos/uso terapéutico , Citocinas/metabolismo , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática , Citometría de Flujo , Humanos , Inmunosupresores/uso terapéutico , Estimación de Kaplan-Meier , Lenalidomida , Leucocitos/citología , Masculino , Dosis Máxima Tolerada , Persona de Mediana Edad , Células Mieloides/citología , Células Neoplásicas Circulantes , Antígeno Prostático Específico/metabolismo , Neoplasias de la Próstata Resistentes a la Castración/inmunología , Talidomida/uso terapéutico , Factores de Tiempo , Resultado del TratamientoRESUMEN
In this study, we examined the effects of cryoprotectant, freezing and thawing, and adenovirus (Adv) transduction on the viability, transgene expression, phenotype, and function of human dendritic cells (DCs). DCs were differentiated from cultured peripheral blood (PB) monocytes following Elutra isolation using granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) for 6 days and then transduced using an Adv vector with an IL-12 transgene. Fresh, cryopreserved, and thawed transduced immature DCs were examined for their: 1) cellular concentration and viability; 2) antigenicity using an allogeneic mixed lymphocyte reaction (MLR); 3) phenotype (HLA-DR and CD11c) and activation (CD83); and 4) transgene expression based on IL-12 secretion. Stability studies revealed that transduced DCs could be held in cryoprotectant for as long as 75 min at 2-8°C prior to freezing with little effect on their viability and cellularity. Further, cryopreservation, storage, and thawing reduced the viability of the transduced DCs by an average of 7.7%; and had no significant impact on DC phenotype and activation. In summary, cryopreservation, storage, and thawing had no significant effect on DC viability, function, and transgene expression by Adv-transduced DCs.
Asunto(s)
Adenoviridae/genética , Criopreservación , Células Dendríticas/citología , Biotecnología , Supervivencia Celular , Células Cultivadas , Crioprotectores/farmacología , Medios de Cultivo , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Citometría de Flujo , Vectores Genéticos , Factor Estimulante de Colonias de Granulocitos y Macrófagos/fisiología , Humanos , Inmunoterapia , Interleucina-12/genética , Interleucina-4/fisiología , Transfección , TransgenesRESUMEN
Energetic electrons generated by electron cyclotron resonance heating are observed to drive instabilities in the quasihelically symmetric stellarator device. The coherent, global fluctuations peak in the plasma core and are measured in the frequency range of 20-120 kHz. Mode propagation is in the diamagnetic drift direction of the driving species. When quasihelical symmetry is broken, the mode is no longer observed. Experimental observations indicate that the unstable mode is acoustic rather than Alfvénic.
RESUMEN
A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult. The development of cancer vaccines is hampered by a range of issues particular to this field of research. On 12th March 2008, the Biotherapy Development Association convened a workshop to discuss issues faced by scientists and clinicians involved in the development of cancer vaccines. This paper is a review of the field, based on discussions held at the BDA workshop, and describes biological barriers encountered in generating effective immune responses to tumours, methodological obstacles encountered in the improvement of immunological monitoring which aims to improve inter-laboratory and inter-trial comparisons, challenges in clinical trial design and problems posed by the lack of specific regulation for cancer vaccines and the impact on their development. Ultimately, a number of general solutions are posed: (1) better patient selection, (2) use of multi-modal treatments that affect several aspects of the immune system at once, (3) a requirement for the development of good biomarkers to stratify patients for selection prior to trial and as surrogates for clinical response and (4) harmonisation of SOPs for immunological monitoring of clinical trials.
Asunto(s)
Vacunas contra el Cáncer/uso terapéutico , Inmunoterapia/métodos , Neoplasias/terapia , Animales , Resistencia a Antineoplásicos/inmunología , Humanos , Inmunoterapia/tendencias , Neoplasias/inmunología , Selección de Paciente , Proyectos de InvestigaciónRESUMEN
This Letter presents theory-based predictions of anomalous electron thermal transport in the Helically Symmetric eXperiment stellarator, using an axisymmetric trapped-electron mode drift wave model. The model relies on modifications to a tokamak geometry that approximate the quasihelical symmetry in the Helically Symmetric eXperiment (particle trapping and local curvature) and is supported by linear 3D gyrokinetic calculations. Transport simulations predict temperature profiles that agree with experimental profiles outside a normalized minor radius of rho>0.3 and energy confinement times that agree within 10% of measurements. The simulations can reproduce the large measured electron temperatures inside rho<0.3 if an approximation for turbulent transport suppression due to shear in the radial electric field is included.
RESUMEN
Differences in the electron particle and thermal transport are reported between plasmas produced in a quasihelically symmetric (QHS) magnetic field and a configuration with the symmetry broken. The thermal diffusivity is reduced in the QHS configuration, resulting in higher electron temperatures than in the nonsymmetric configuration for a fixed power input. The density profile in QHS plasmas is centrally peaked, and in the nonsymmetric configuration the core density profile is hollow. The hollow profile is due to neoclassical thermodiffusion, which is reduced in the QHS configuration.
RESUMEN
Dendritic cell (DC) expansion is regulated by the hematopoietic growth factor fms-like tyrosine kinase 3 ligand (Flt3L). DCs are critical to the control of tumor growth and metastasis, and there is a positive correlation between intratumoral DC infiltration and clinical outcome. In this report, we first demonstrate that single intravenous (i.v.) injections of adenovirus (Adv)-Flt3L significantly increased splenic dendritic, B, T and natural killer (NK) cell numbers in both normal and mammary tumor-bearing mice. In contrast, the numbers of DCs and T cells infiltrating the tumors were not increased. Consistent with the minimal effect on immune cell infiltration, i.v. Adv-Flt3L injections had no therapeutic activity against orthotopic mammary tumors. In addition, we noted tumor and Adv-Flt3L expansion of Gr1(+)CD11b(+) immature myeloid suppressor cells (IMSCs), which may inhibit the therapeutic efficacy of Adv-Flt3L-expanded DCs.
Asunto(s)
Terapia Genética , Neoplasias Mamarias Animales/terapia , Proteínas de la Membrana/genética , Bazo/inmunología , Linfocitos T/inmunología , Adenoviridae/genética , Animales , Células Dendríticas/inmunología , Femenino , Vectores Genéticos/administración & dosificación , Vectores Genéticos/genética , Inyecciones Intravenosas , Recuento de Linfocitos , Linfocitos Infiltrantes de Tumor/inmunología , Ratones , Ratones Endogámicos BALB C , Insuficiencia del TratamientoRESUMEN
Measurements of plasma flow damping have been made in the helically symmetric experiment using a biased electrode to impulsively spin the plasma. There are two time scales in the evolution of the plasma flow, for both the spin-up and relaxation. Compared to a configuration with the quasisymmetry broken, the flow in the quasisymmetric configuration rises more slowly and to a higher value at bias turn-on, and decays more slowly at bias turn-off. The decays of the flows are significantly faster than the neoclassical prediction.
RESUMEN
Fms-like tyrosine kinase 3 ligand (Flt3L) has multiple effects on the hematopoietic and immune systems. Further, preclinical studies have suggested potential therapeutic activity against cancer. Flt3L is a potent hematopoietic cytokine, capable of stimulating the expansion and differentiation of hematopoietic progenitor and stem cells. Administration of Flt3L mobilizes hematopoietic cells from the bone marrow (BM) into the blood, lymphoid organs, and parenchymal tissues. This mobilization activity, especially effective in combination with granulocyte colony stimulating factor (G-CSF), has stimulated studies of Flt3L in hematopoietic stem cell (HSC) transplantation. In addition to its effects on hematopoietic stem and progenitor cells, Flt3L has been shown to increase the frequency and number of dendritic cells (DCs) within the circulatory system and solid organs. DC expansion by Flt3L has been the focus of preclinical and clinical studies on antigen (Ag) specific T-cell mediated immunity. The mechanism for the augmentation of T-cell mediated immunity has yet to be completely identified, although Flt3L's ability to expand DCs in lymphoid and non-lymphoid tissues is involved. This expansion occurs primarily with DCs, which secrete interleukin (IL) 12. Consistent with the expansion of this DC population, treatment with Flt3L enhances T-cell mitogenesis and preferentially induces type 1 T-cell responses. However, the DCs resulting from Flt3L administration are immature, leading in some studies to the induction of tolerance. This review focuses on the effects of Flt3L on DCs and other effector populations, and on its potential activity as a therapeutic agent for cancer, alone and in combination with vaccines.
Asunto(s)
Vacunas contra el Cáncer/metabolismo , Vacunas contra el Cáncer/uso terapéutico , Proteínas de la Membrana/metabolismo , Proteínas de la Membrana/uso terapéutico , Proteínas Proto-Oncogénicas/fisiología , Proteínas Tirosina Quinasas Receptoras/fisiología , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/fisiología , Adyuvantes Inmunológicos/uso terapéutico , Animales , Vacunas contra el Cáncer/administración & dosificación , Ligandos , Proteínas de la Membrana/administración & dosificación , Proteínas de la Membrana/fisiología , Tirosina Quinasa 3 Similar a fmsRESUMEN
Fms-like tyrosine kinase (Flt3L) is a potent stimulator of hematopoietic progenitor cell (HPC) expansion and mobilization; however, this requires 7-10 days of administration. We investigated whether sustained delivery of Flt3L using a poloxamer-based matrix (PG) could accelerate and/or improve the hematopoietic activity of Flt3L in mice. A single injection of PG-Flt3L stimulated significantly more rapid and greater HPC mobilization to the spleen and peripheral blood than the daily injection of Flt3L formulated in saline. Pharmacokinetic analysis demonstrated that the formulation of Flt3L in PG prolonged its elimination (Tbeta) half-life (2.3-fold) and increased its bioavailability (>two fold) and the time to maximum serum concentration (T(max)) (2.7-fold). Further, coadministration of G-CSF and PG-Flt3L allowed lower doses of Flt3L to be active, with significantly greater hematopoietic and mobilization activity, compared to the same total dose of G-CSF, Flt3L or G-CSF and Flt3L formulated in saline. These data demonstrate that formulation of Flt3L in PG significantly accelerates and increases HPC expansion and mobilization. The observation of increased bioactivity by PG-Flt3L in rodents suggests the potential for improved clinical efficacy of Flt3L by reducing the time required for HPC mobilization.
Asunto(s)
Movilización de Célula Madre Hematopoyética , Proteínas de la Membrana/administración & dosificación , Poloxámero/administración & dosificación , Animales , Células de la Médula Ósea/efectos de los fármacos , Química Farmacéutica , Relación Dosis-Respuesta a Droga , Femenino , Factor Estimulante de Colonias de Granulocitos/farmacología , Proteínas de la Membrana/farmacocinética , Proteínas de la Membrana/farmacología , Ratones , Ratones Endogámicos BALB C , Bazo/citologíaRESUMEN
We examined the ability of immunization with sequential adenovirus/plasmid DNA vectors expressing human wild-type p53 to stimulate a type 1 T-cell response and induce protection against challenge from a metastatic tumor that expresses mutated murine p53. We found that tumor protection and an antigen (Ag)-specific immune response were enhanced by prior injection of Flt3 ligand (Flt3L) at a dose and schedule that significantly increased dendritic cell (DC) number and frequency. Preliminary studies using enzyme-linked immunospot and Winn assays suggested that Ag-specific CD8 cells, with their significant increase in IFN-gamma-secreting activity (Tc1 cells), were responsible for the tumor protection. The delayed-type hypersensitivity response to p53 was increased in mice immunized with p53 alone or p53 and Flt3L compared with a negative control. In contrast, spleen cells from mice immunized with p53 and Flt3L exhibited a higher Ag-specific proliferative response than mice immunized with p53 alone. The frequencies of Ag-specific IFN-gamma and interleukin (IL)-4-secreting cells were determined using an enzyme-linked immunospot assay, which demonstrated that the frequency of IFN-gamma-secreting cells was significantly higher in mice immunized with p53 and Flt3L than in mice receiving Flt3L, excipient, or p53 treatment alone. In contrast, the frequency of IL-4-secreting cells did not differ significantly among these groups. We also observed an increased frequency of IL-12 and IFN-gamma-secreting cells (but not IL-4 or IL-10) in the spleens of mice immediately after 10 days of Flt3L treatment, which was also the day of p53 priming. This observation supports the likelihood that there are multiple mechanisms of Flt3L adjuvant activity, including expansion of DC and type 1 T-cell number. Overall, these results suggest that immunization with p53 genetic sequences after in vivo expansion of DC, using Flt3L, provides a useful strategy to induce p53-specific, and protective, type 1 T-cell responses.
Asunto(s)
Epítopos de Linfocito T/inmunología , Genes p53/inmunología , Proteínas de la Membrana/inmunología , Linfocitos T/inmunología , Adenoviridae/genética , Animales , Células Dendríticas/inmunología , Femenino , Genes p53/genética , Humanos , Hipersensibilidad Tardía/inmunología , Inmunización , Interferón gamma/inmunología , Interferón gamma/metabolismo , Interleucinas/inmunología , Interleucinas/metabolismo , Activación de Linfocitos/inmunología , Neoplasias Mamarias Experimentales/genética , Neoplasias Mamarias Experimentales/inmunología , Neoplasias Mamarias Experimentales/prevención & control , Ratones , Ratones Endogámicos BALB C , Mutación , Plásmidos/genética , Plásmidos/inmunología , Bazo/citología , Bazo/inmunología , Bazo/metabolismoRESUMEN
Flt-3 ligand (FL), a recently described growth factor affecting early hematopoietic progenitor cells, can also support the expansion of dendritic cells secreting IL-12. Since type 2 T cells predominate in asthma and IL-12 prevents the differentiation of naive T lymphocytes to a type 2 phenotype, we hypothesized that FL could prevent the development of asthma-like conditions in the ovalbumin mouse model. We found that co-administration of FL during ovalbumin sensitization abrogated late allergic responses, but had no effect on early allergic responses. Airway hyperresponsiveness to methacholine was also blocked by FL treatment. Analysis of bronchoalveolar lavage (BAL) fluid demonstrated a significant reduction in eosinophils, with concomitant decreases in IL-5 and increases in IFN-gamma levels. However, there was no change in BAL fluid IL-4 and serum IgE levels. These data suggest that FL treatment prevents ovalbumin-induced asthma in the mouse and may provide a useful adjuvant in the treatment of human asthma.
Asunto(s)
Asma/prevención & control , Células Dendríticas/metabolismo , Interleucina-12/metabolismo , Proteínas de la Membrana/uso terapéutico , Células Th2/inmunología , Resistencia de las Vías Respiratorias/efectos de los fármacos , Alérgenos/administración & dosificación , Alérgenos/inmunología , Alérgenos/toxicidad , Animales , Asma/tratamiento farmacológico , Asma/inmunología , Líquido del Lavado Bronquioalveolar/química , Diferenciación Celular/efectos de los fármacos , Esquema de Medicación , Femenino , Inmunización , Inmunoglobulina E/sangre , Interferón gamma/análisis , Interleucina-4/análisis , Interleucina-5/análisis , Proteínas de la Membrana/administración & dosificación , Proteínas de la Membrana/farmacología , Cloruro de Metacolina/farmacología , Ratones , Ratones Endogámicos BALB C , Modelos Animales , Ovalbúmina/administración & dosificación , Ovalbúmina/inmunología , Ovalbúmina/toxicidad , Eosinofilia Pulmonar/prevención & controlRESUMEN
OBJECTIVE: Mechanisms of T-cell stimulation by Flt3 ligand (Flt3L) and granulocyte-macrophage colony-stimulating factor (GM-CSF) remain unclear. Herein, we compared the effects of Flt3L and GM-CSF on the expansion of dendritic cells (DC) and T-cell subsets and cytokine expression. METHODS: Naïve and effector/memory T cells were analyzed by flow cytometry (FC). CD4(+) and CD8(+) T cells and CD11c(+)CD11b(dull/-)(DC1) and CD11c(+)CD11b(+) (DC2) subsets were isolated and the frequency of IFN-gamma-, IL-12- (type 1) and IL-4-, IL-10 (type 2)-producing cells and cytokine mRNA expression evaluated. RESULTS: Flt3L expanded both DC1 and DC2 subsets with a significantly higher percentage and number of DC1 than DC2, while GM-CSF preferentially expanded the DC2 subset. Isolated DC1 from Flt3L-injected mice had significantly higher levels of IL-12 (p40) than IL-10, while the converse occurred with DC2. The numbers of naïve and memory T cells were elevated in mice that received Flt3L or GM-CSF. However, the number of memory CD4(+) and CD8(+) T cells was significantly increased in Flt3L as compared to GM-CSF cohorts. While GM-CSF increased the frequency of both type 1 and type 2 cytokine-producing cells, Flt3L significantly augmented the frequency of type 1 T cells. CONCLUSIONS: In contrast to GM-CSF, Flt3L preferentially induces the expansion of type 1 T cells. The mechanism of Flt3L-induced T-cell stimulation is associated with the expansion of the IL-12 (p40)-producing DC1 and memory T cells.
Asunto(s)
Células Dendríticas/inmunología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/farmacología , Proteínas de la Membrana/farmacología , Factor de Células Madre/farmacología , Subgrupos de Linfocitos T/inmunología , Animales , Linfocitos T CD4-Positivos/efectos de los fármacos , Linfocitos T CD4-Positivos/inmunología , Linfocitos T CD8-positivos/efectos de los fármacos , Linfocitos T CD8-positivos/inmunología , Separación Celular/métodos , Citocinas/genética , Células Dendríticas/clasificación , Células Dendríticas/citología , Células Dendríticas/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática/métodos , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/inmunología , Interferón gamma/biosíntesis , Interferón gamma/genética , Interleucina-12/genética , Interleucina-4/biosíntesis , Interleucina-4/genética , Ratones , Ratones Endogámicos BALB C , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Bazo/inmunología , Subgrupos de Linfocitos T/citología , Subgrupos de Linfocitos T/efectos de los fármacosRESUMEN
The eradication of autoreactive T cells by high dose therapy and stem cell transplantation and the resultant alterations in the immunologic network, thymic reeducation, and peripheral tolerance provide treatment mechanisms for autoimmune and inflammatory diseases. One outcome of autologous stem cell transplantation is a significant decrease in the CD4:CD8 ratio due to a loss in CD4+ cells and a depression in T cell function. Mechanistically, the loss of T cell function is associated with an increased frequency of circulating monocytes, their expression of Fas ligand (FasL), and a high frequency of apoptotic CD4+ T cells. This suggests that activated Fas+ CD4+ lymphocytes interact with FasL+ monocytes. resulting in apoptosis, preferential deletion of CD4+ T cells, an inversion in the CD4:CD8 ratio, and depressed T cell function. These observations suggest the potential for immune regulation using stem cell manipulation or posttransplant cytokine administration as therapeutic strategies for autoimmune/inflammatory diseases.
Asunto(s)
Artritis Reumatoide/terapia , Citocinas/metabolismo , Trasplante de Células Madre Hematopoyéticas/métodos , Apoptosis/fisiología , Artritis Reumatoide/inmunología , Relación CD4-CD8 , Linfocitos T CD4-Positivos/inmunología , Proteína Ligando Fas , Glicoproteínas de Membrana/metabolismo , Monocitos/inmunología , Acondicionamiento Pretrasplante , Tolerancia al Trasplante/efectos de los fármacos , Trasplante Autólogo , Resultado del TratamientoRESUMEN
We recently found that mobilized peripheral blood stem cell (PSC) products (from both cancer patients and normal donors) contain high levels of CD14+ monocytes, which can inhibit the proliferation of allogeneic and autologous T cells. We found in our studies that using CD14+ monocytes from mobilized PSC products (from normal and cancer patient donors), normal apheresis products or normal peripheral blood (PB) can affect lymphocyte function and apoptosis-dependent T cell activation. However, it appears that the apoptosis is dependent on the frequency of monocytes, which is increased by both mobilization and apheresis. Both phytohemagglutinin (PHA)- and interleukin (IL)-2-induced proliferation of steady-state peripheral blood mononuclear cells (PBMC) were markedly inhibited by co-culture with irradiated CD14+ monocytes, although inhibition was significantly greater with PHA than with IL-2 stimulation. IL-2 (predominately CD56+ NK cells) or anti-CD3 monoclonal antibody (mAb) and IL-2-expanded lymphocytes (activated T cells) were inhibited by PSC monocytes to a significantly greater level as compared to steady-state lymphocytes. Indeed, no inhibition of T cell proliferation was observed when lymphocytes were co-cultured in the absence of mitogenic or IL-2 stimulation. In contrast, an increased proliferation was observed in co-cultures of CD14+ monocytes and steady-state or activated lymphocytes without mitogenic stimulation. Cell cycle analysis by flow cytometry revealed a significant increase in hypodiploid DNA, in a time-dependent manner, following co-culture of monocytes and PBMC in PHA, suggesting that T cell apoptosis occurred during PHA-induced activation. These results demonstrate that PSC-derived monocytes inhibit T cell proliferation by inducing the apoptosis of activated T cells and NK cells, but not steady-state cells. This suggests a potential role for monocytes in the induction of peripheral tolerance following stem cell transplantation.
Asunto(s)
Apoptosis/fisiología , Monocitos/fisiología , Células Madre Neoplásicas/fisiología , Células Madre/fisiología , Linfocitos T/fisiología , Anticuerpos Monoclonales/farmacología , Apoptosis/efectos de los fármacos , Complejo CD3/inmunología , División Celular , Citometría de Flujo , Técnica del Anticuerpo Fluorescente , Humanos , Técnicas In Vitro , Interleucina-2/farmacología , Monocitos/efectos de los fármacos , Fitohemaglutininas/farmacología , Linfocitos T/efectos de los fármacosRESUMEN
Co-incubation of a replication-deficient, recombinant adenovirus carrying the wild-type p53 gene (rAd-p53) and hematopoietic stem cell (HSC) products from patients with breast cancer can significantly reduce tumor cell contamination. Whereas this approach provides a powerful tumor cell purging strategy, potential detrimental effects on the HSC population have not been investigated. The ability of human HSC to reconstitute hematopoiesis in severe combined immunodeficient (SCID) mice and to undergo secondary transplantation provides the only nonclinical measure of self-renewing, stem cell function. The objective of this study was to investigate whether co-incubation with rAd-p53 compromised the SCID repopulating activity (SRA) of HSC. Granulocyte colony-stimulating factor-mobilized human CD34+ cells were co-cultured with rAd-p53 at our targeted clinical dose, and the ability of these cells to establish multilineage hematopoiesis in sublethally irradiated, nonobese diabetic (NOD)-SCID mice was investigated. The persistence of human cells in the mice was investigated by flow cytometry, granulocyte-macrophage colony-forming unit assay, and polymerase chain reaction of human Alu sequences. Further, limiting dilution analysis provided a quantitative comparison between the SRA of CD34+ cells co-incubated with rAd-p53 and control CD34+ cells (no rAd-p53 co-incubation). We conclude that co-incubation with rAd-p53 has little effect on the SRA of HSC.
Asunto(s)
Purgación de la Médula Ósea , Genes p53 , Terapia Genética , Trasplante de Células Madre Hematopoyéticas , Células Madre Hematopoyéticas/fisiología , Adenoviridae , Animales , Purgación de la Médula Ósea/métodos , Femenino , Vectores Genéticos , Factor Estimulante de Colonias de Granulocitos/farmacología , Hematopoyesis , Movilización de Célula Madre Hematopoyética , Humanos , Ratones , Ratones Endogámicos NOD , Ratones SCIDRESUMEN
BACKGROUND: When stem-cell grafts are infused into the venous circulation and stem/progenitor cells egress from BM, pulmonary capillary beds are the first microcirculation site that they encounter. This provides the potential for circulating progenitor cells to be trapped in the pulmonary circulation. METHODS: We compared the number of progenitor cells [CD34(+) cells, colony-forming unit-granulocyte-macrophage (CFU-GM), CD34(+) CD41(+) cells and CFU-megakaryocyte (CFU-meg)] and their expression of cell-adhesion molecules (CAM) in samples taken simultaneously from radial arteries and central veins of 21 patients following PBSC mobilization. RESULTS: The mean (+/- SD) frequency of progenitor cells in the radial arteries was reduced to 79% +/- 25% for CD34(+) cells, 73% +/- 27% for CFU-GM, 77% +/- 25% for CD34(+) CD41(+) cells and 70% +/- 29% for CFU-meg of the number in the central veins. This suggests that some progenitor cells might be trapped in the lung. No association between progenitor-cell expression of CAM and pulmonary trapping was observed. DISCUSSION: Our data demonstrate pulmonary trapping of PBSC during mobilization, suggesting a potential inhibitory effect on PBSC harvest and medullary trafficking following graft infusion. However, the impact associated with pulmonary PBSC trapping may be negligible in the clinical setting if sufficient cells are infused.